• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Invitae | Genelex

Invitae | Genelex

Pharmacogenetics Makes Precision Medicine Possible

  • For Patients
    • Conditions
    • Affected Drugs
    • What is PGx?
    • Resources
    • FAQs
  • For Providers
    • Conditions
    • Resources
    • Order Testing Supplies
  • Test Menu
  • Clinical Trials
  • About
    • Lab Accreditations
    • Genelex Team
    • Contact Us
  • Log In
Home / Patients / Conditions / Heart Disease

CONDITIONS

Pharmacogenetics and Cardiovascular Conditions

Cancer

Depression

Epilepsy

Cardiovascular

Chronic Pain

Diabetes

HIV

Acid Reflux

Millions of Americans currently take cardiovascular medications to treat or prevent heart disease. Major pharmacogenetic strides over the past decade have led the way to leveraging genetic information to guide therapies for cardiovascular patients.

The majority of heart disease medications are metabolized by three enzymes in the liver: CYP2D6, CYP2C9, and CYP2C19. [14]

Other genetic pathways include CYP2C9, CYP3A4, CYP3A5, VKORC1, F2/Factor II, F5/Factor V Leiden, and SLCO1B1. Your genes are the main factor determining the level of these enzymes primarily found in your liver. If you have too much of the enzyme, you process the medication too quickly: too little of the enzyme and the medication builds up in your bloodstream, potentially causing adverse reactions or side effects.

PGx AND HEART DISEASE

Learn How Your Heart, Medications, and Genes Work Together

Pharmacogenetic testing complements current efforts to optimize drug options for heart disease and leans towards effective and personalized care —using drug-drug and drug-gene interaction software, you'll get a report highlighting potential options for you and your physician to discuss.

Population Frequency of Cytochrome P450 (CYP) Metabolizer Types [5]

Poor 
(no or low enzyme levels)
Intermediate 
(reduced enzyme levels)
normal 
(normal enzyme levels)
Rapid or
Ultra Rapid
Metabolizer 
(high enzyme levels)
CYP2D6* 4-7% 9-35% 50-90% 2-3%
CYP2C9 3% 30% 68% N/A
CYP2C19* 2-20% 24-36% 14-44% 30%

*CYP2C19 variability depends on ethnicity.
*CYP2D6 Variability depends on ethnicity and classification of Intermediate activity

Additional heart disease medications that are impacted by your genetics:[15]

Trade NameDrug
Brilinta®ticagrelor
Coreg®carvedilol
Coumadin®, Jantoven®warfarin
Crestor®rosuvastatin
Effient®prasugrel
Inderal®, InnoPran®, Hemangeol®propranolol
Lopressor®, Toprol®metoprolol
Plavix®clopidogrel
Rythmol®propafenone

Patient Resources

Understanding Your Results
Insurance Information
Talking to Your Healthcare Provider
Requisition Form
Frequently Asked Questions
Genelex Blog

Improving Drug Efficacy

Genelex's pharmacogenetic testing bridges the gap in understanding how the role of PGx can help in patient care and offers a simple DNA test and provides you with a report of the results that you and your doctor can discuss.

Footer

CONTACT US

(800) 837-8362
info@genelex.com

3101 Western Ave.
Suite 100
Seattle, WA 98121

HELPFUL INFORMATION

What is PGx?
Test Menu
Conditions
Affected Drugs
FAQs
References

ABOUT GENELEX

Blog
News
Genelex Team
Lab Accreditations
Contact Us
Privacy Practices
Privacy Policy

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

KEEP IN TOUCH

Stay in the loop with news and updates from Genelex and be among the first to know when new tests become available.